31 March 2022

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Directorate Changes

Further to its announcement of 16 December 2021, RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon^TM), is pleased to announce the appointments, with immediate effect, to the Board of Lachlan Smith as Chief Financial Officer, and Dr Iain Anthony as Director of Clinical and Regulatory Affairs.

Iain joined the Company in November 2021 as Director of Clinical and Regulatory Affairs and brings a wealth of relevant cardiovascular medical device experience to the Company. He has over 15 years' experience in the medical device industry in both commercial and NHS settings.  He was recruited from the Swiss based MedAlliance where he was Director of Pre-Clinical/Clinical Regulatory Affairs focusing on development and approval of drug coated coronary and peripheral angioplasty balloons.  Prior to this, Iain was Head of Clinical Affairs at Terumo Aortic where he developed his knowledge and experience of the global vascular graft business.

Lachlan joined the Company in December 2021 as Chief Financial Officer and is a Fellow of the Association of Chartered Certified Accountants. With 20 years' experience in accounting and financial management and digital transformation, the last 14 years of which were spent in strategic leadership roles at high growth businesses. Prior to joining RUA Life Sciences, Lachlan served as Finance Director at technology companies Silver Cloud Smarter Technology and Equator.

Since their respective appointments, both Iain and Lachlan have been playing key roles in the business providing the expertise to lead the revised regulatory strategy and the detailed financial planning to maximise contribution from the vascular graft range by prioritising both manufacturing efforts and sales focus.

Further information in accordance with paragraph (g) of Schedule Two of the AIM Rules for Companies is set out at the end of this announcement.

Caroline Stretton, Group Managing Director of the Company, commented: "The Board appointments of Iain and Lachlan will ensure that we have the right management expertise to support the growth of the Group and enable the vascular graft business to accelerate its clinical study plans for earlier entry into global markets."

Bill Brown, Chairman of the Company, commented: "I am delighted to be welcoming two new members to our Board who bring with them a great deal of knowledge and expertise and look forward to working with them in the coming years."

For further information contact:

RUA Life Sciences

Bill Brown, Chairman                                                           Tel: +44 (0)1294 317073  

Caroline Stretton, Group Managing Director                       Tel: +44 (0)1294 317073

Shore Capital (Nominated Adviser and Joint Broker)   Tel: +44 (0)20 7408 4080 

Tom Griffiths/David Coaten                                             

Cenkos Securities plc (Joint Broker)                             Tel: +44 (0)20 7397 8900

Max Gould (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon^TM, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-Eon^TM, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are: